Fabry Disease


Article Author:
Syed Rizwan Bokhari
Hassam Zulfiqar


Article Editor:
Anis Hariz


Editors In Chief:
Stephen Leslie
Karim Hamawy


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
6/6/2019 2:06:57 PM

Introduction

Fabry disease is a multi-systemic, X-linked recessive lysosomal storage disease caused by decreased activity of alpha-Galactosidase A and results in lysosomal accumulations of neutral glycosphingolipids, globotriaosylceramide GL-3. Angiokeratoma corporis diffusum is the typical skin lesion seen in Fabry disease and is linked to renal involvement, especially proteinuria. Young adults presenting with a cerebrovascular event in association with myocardial infarction and renal dysfunction should be considered for Fabry disease. Abnormalities in almost any part of the body can be found with more predisposition of the skin, eye, kidney, heart, brain, and peripheral nervous system.[1][2][3]

Etiology

Researchers have identified hundreds of mutations causing Fabry disease in the gene for alpha-Gal A, which is located on the X chromosome. Deficiency of alpha-Gal A is the main cause for the lysosomal buildup of glycosphingolipids, principally the cerebroside trihexosides. Progressive glycolipid accumulation with resultant swelling and proliferation of endothelial cells leads to renal failure in the third to the fourth decade, cardiac disease, strokes, and early death. Classic Fabry phenotype is associated with these mutations and presents with multisystem involvement. Milder forms with missense mutations are restricted to cardiac abnormalities.[4][5][6]

Epidemiology

Prevalence in white, male populations has been linked to Fabry disease in a wide range, approximately 1:17,000 to 1:117,000. Classic Fabry disease mutations are seen in approximately 1:22,000 to 1:40,000 males and atypical presentations are associated with about 1:1000 to 1:3000 males and 1:6000 to 1:40,000 females.

Although it is an under-diagnosed condition, the disease is seen in all racial and ethnic groups.

Pathophysiology

The lysosomal alpha-galactosidase A (alpha-Gal A) deficiency is the main metabolic defect. It is required for the breakdown of the terminal galactose from globotriaosylceramide (Gb3) and leads to accumulation of Gb3 in various cells and tissues including skin, eye, kidney, heart, brain, and peripheral nervous system.

Vascular accumulation secondary to increased endothelial proliferation may manifest as vascular occlusion, ischemia, and infarction. The most common site for vascular dilatation is the vertebrobasilar arteries followed by smaller cerebral vessels. Young patients presenting with stroke in the setting of Fabry disease have low levels of thrombomodulin (TM) and elevated levels of plasminogen activator inhibitor (PAI) suggestive of the prothrombotic nature of the disease. Postulated mechanisms for stroke in young patients with Fabry disease have been linked to nitric oxide and non-nitric oxide-dependent endothelial proliferation and dilation and abnormal endothelial nitric oxide synthase (eNOS) activity. Other common sites of Gb3 accumulation include autonomic ganglia, dorsal root ganglia, renal glomerular, tubular and interstitial cells, cardiac muscle cells, vascular smooth muscle cells, valvular fibrocytes, cardiac conduction fibers and the cornea.

Globotriaosylceramide (Gb3) accumulation in the kidney frequently occurs in glomerulus followed by deposits in the distal tubule. The preference for Gb3 deposits in these locations is associated with the development of early proteinuria and polyuria. The mechanism of renal sinus cysts formation associated with Fabry disease is not well understood.[7][8][9]

Histopathology

Skin biopsy usually reveals high lipid content. Lipids may also be found inside muscle fibers, endothelial cells, and ganglion cells.[10]

History and Physical

History can reveal high blood pressure in association with renal dysfunction. A thorough medical history should be taken with specific attention for heat intolerance with abnormally decreased sweat and tear production, severe heart disease, and cerebrovascular accident (CVA). Attention should be paid to family history, considering the X-linked pattern of genetic inheritance. Affected males may present with the disease appearing in childhood and early adolescence with the involvement of any organ system. However, it usually presents with painful acroparesthesias, hypohidrosis, gastrointestinal symptoms, namely abdominal cramping, and diarrhea. Skin manifestations include microvascular lesions that can appear as small petechiae around the umbilicus, eye manifestations such as lenticular opacities and corneal dystrophy.

The course of the disease is variable but usually manifests as polyuria, polydipsia, and proteinuria leading to end-stage renal disease (ESRD), cardiac conduction and valvular defects, CVA, and other neurological manifestations in the third to the fourth decade of life. Some patients may present with complaints of lymphadenopathy and problems adjusting to heat or cold and strenuous exercise.

Evaluation

Practitioners should highly suspect Fabry disease should in individuals presenting with the signs and symptoms mentioned above, along with the information gleaned from a thorough personal and family history and physical examination. A basic metabolic profile looking for electrolytes and renal profile, urine sediment for oval fat bodies, ECG, as well as an echocardiogram looking for conduction and structure abnormalities is helpful. Radiological investigations like chest x-ray, CT, CTA, MRI, MRA, and MR spectroscopy can be considered for neurological features. Specific diagnosis is made by documentation of low alpha-Gal A activity in leukocytes or plasma. If enzyme assay or genetic testing are not available, biopsy of skin or kidney can help establish the diagnosis. Glycolipid deposits will characterize the biopsy. Electron microscope examination of renal biopsy shows concentric layers of inclusions called myeloid or zebra bodies.[11]

Treatment / Management

This disease cannot be completely cured. Supportive treatment of Fabry disease is to replace the deficient enzyme, alpha-galactosidase A (aglisadase alpha or beta) as soon the diagnosis is made, regardless of presence or absence of clinical manifestations in affected males and patients on renal replacement therapy. Female carriers and affected males with decreased levels of Alpha-Gal A should get enzyme replacement only in the presence of kidney, heart, or neurological features. Patients on long-term dialysis should also receive enzyme replacement therapy. Hypertension in these patients should be managed with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.[12][13][1]

Either of enzyme Alpha or beta replacement infusions should be given every two weeks according to body weight calculations. Precautions should be taken considering infusion-related reactions. Slow infusion over one to two hours along with prior administration of antipyretics should be considered.

Fabry disease patients with end-stage renal disease can be safely considered for renal transplantation with the continued enzyme replacement post-transplant.

Differential Diagnosis

Prognosis

Once an individual develops a first stroke, the risk of subsequent strokes is common.

Heterozygous females tend to have much milder symptoms compared to males.

Complications

  • Angiokeratomas
  • Cardiomegaly
  • Arrhythmias
  • Acroparesthesia
  • Hearing loss
  • Vertigo
  • Altered sweating
  • Corneal verticillata

Consultations

A neurologist who specializes in stroke and Fabry disease

Cardiologist if the stroke is embolic

Nephrologist for kidney failure

Pearls and Other Issues

Patients with Fabry disease needs to be managed in a multidisciplinary team approach, with input and regular follow up from physicians in neurology and ophthalmology, in addition to experts in managing diseases of kidney, heart, and skin.

Every year patient should be screened for new onset symptoms with close monitoring of complete blood count and renal function panel, along with workup for proteinuria. Cardiology monitoring with imaging and electrophysical studies should be done within 1 to 2 years.

Screening for family members includes an enzymatic assay for deficient alpha-Gal A activity in both symptomatic male and female relatives. There is no supportive evidence for routine prenatal screening and enzyme replacement in infants.

Enhancing Healthcare Team Outcomes

Fabry disease is a rare X-linked lysosomal disorder that results in excessive deposition of lipids in the tissues. Young patients usually present with stroke, skin lesions, heart attack, or renal failure. Once the diagnosis is made a multidisciplinary approach is vital. The earlier the diagnosis, the better the prognosis. If the disorder is identified during pregnancy, the family will need prenatal counseling.

The role of the nurse in education is indispensable. The patient and the family need to know about the course of the disease, lifestyle modifications, and the need to follow up.

Since these patients are prone to strokes, the pharmacist must be fully aware of the types of antiplatelet agents that can be used as prophylaxis. If the stroke is embolic, then warfarin has to be used, and the patient must be told to get regular INR checks. Since the patients are also prone to painful neuropathies, the pharmacist should be familiar with anticonvulsants which are effective in such disorders. Finally, the pharmacist must be fully aware of the enzyme replacement therapies available. The earlier the enzymes are started, the better the outcomes. 

Patients with Fabry disease also develop renal, and liver failure, and hence the transplant team should be notified to determine if the patient is eligible.

Finally, the physical and occupational therapist should be consulted to assist with ambulation, use of an ambulatory device and how to perform daily living activities.[6][14][15] (Level III)

Outcome

Fabry disease is heterogeneous in its presentation, but most of its complications are life-threatening. Because the disease is rare, there are no long-term randomized trials, and most of the evidence is short-term and based on anecdotal case reports and small retrospective case series. End-stage heart and liver disease are often the cause of premature death. Various studies show that the ten-year survival is very low despite enzyme replacement. While kidney transplant has been shown to prolong survival, it is not curative and also subjects the patient to additional morbidity from the side effects of the immunosuppressant drugs. Given this, an interprofessional approach that includes nurses and therapists should try to offer the patient a decent quality of life. [16][17](Level V)


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Fabry Disease - Questions

Take a quiz of the questions on this article.

Take Quiz
A 12-year-old boy is seen with complaints of severe burning pain in his extremities. He is told that he had a congenital disorder and that the disorder would one day affect his kidneys and heart. The examination also reveals the presence of numerous dark skin lesions over the lower trunk. Biopsy of the lesions reveals an excess of ceramide. What is the diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following organ systems is unlikely to be affected by Fabry disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Who is most likely to be diagnosed with Fabry disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is an X-linked recessive lysosomal storage disorder?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 14 year old boy presents for evaluation complaining of shooting pains in his hands and feet. You have never seen the patient before but have heard your colleague talk about his dramatic nature. However, he seems to be genuinely distressed by these pains. Your exam is otherwise normal except for purplish papules primarily in his groin region. He denies any new powders or detergents. Which of the following is not a complication of this condition?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
27 year old man presents with complaints of uncontrolled hypertension, progressive derangement in renal profile, decreased vision, and burning pain in his fingers of hands and feet. Physical examination showed small red papules over trunk and lower limbs. There was family history of diabetes mellitus and strokes. Patient was referred to ophthalmologist that revealed concentric onion skin appearing deposits on retina with no evidence of diabetic retinopathy. His labs showed, Hb 8.9 mg/dl, TLC 5.5, creatinine 2.7, HbA1c 4.6, urine showed protein 2 +, blood 2 +, and no casts. What is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 15-year-old presented with complaints of abdominal pain, cold intolerance, and burning pain in his extremities. Physical examination showed small red papules over trunk and lower limbs. Eye exam revealed tortuosity of vessels and concentric onion skin appearing deposits on the retina with no evidence of diabetic retinopathy. Lab tests revealed renal dysfunction with mild proteinuria and hematuria. Renal biopsy was done which revealed enlarged epithelial cells with a foamy appearance and multiple small clear vacuoles. What is the diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 20 year old male with a history of febrile episodes, painful paresthesias, and proteinuria is noted to have 3 mm, red, telangiectatic papules around the umbilicus and on the scrotum. The most likely diagnosis is:



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Fabry Disease - References

References

Wanner C,Arad M,Baron R,Burlina A,Elliott PM,Feldt-Rasmussen U,Fomin VV,Germain DP,Hughes DA,Jovanovic A,Kantola I,Linhart A,Mignani R,Monserrat L,Namdar M,Nowak A,Oliveira JP,Ortiz A,Pieroni M,Spada M,Tylki-Szymańska A,Tøndel C,Viana-Baptista M,Weidemann F,Hilz MJ, European expert consensus statement on therapeutic goals in Fabry disease. Molecular genetics and metabolism. 2018 Jul     [PubMed]
Lenders M,Brand E, Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease. Journal of the American Society of Nephrology : JASN. 2018 Aug 9     [PubMed]
Wasserstein MP,Caggana M,Bailey SM,Desnick RJ,Edelmann L,Estrella L,Holzman I,Kelly NR,Kornreich R,Kupchik SG,Martin M,Nafday SM,Wasserman R,Yang A,Yu C,Orsini JJ, The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants. Genetics in medicine : official journal of the American College of Medical Genetics. 2018 Aug 10     [PubMed]
Chan B,Adam DN, A Review of Fabry Disease. Skin therapy letter. 2018 Mar     [PubMed]
Del Pino M,Andrés A,Bernabéu AÁ,de Juan-Rivera J,Fernández E,de Dios García Díaz J,Hernández D,Luño J,Fernández IM,Paniagua J,Posada de la Paz M,Rodríguez-Pérez JC,Santamaría R,Torra R,Ambros JT,Vidau P,Torregrosa JV, Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney     [PubMed]
Ortiz A,Germain DP,Desnick RJ,Politei J,Mauer M,Burlina A,Eng C,Hopkin RJ,Laney D,Linhart A,Waldek S,Wallace E,Weidemann F,Wilcox WR, Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular genetics and metabolism. 2018 Apr     [PubMed]
Sweet ME,Mestroni L,Taylor MRG, Genetic Infiltrative Cardiomyopathies. Heart failure clinics. 2018 Apr     [PubMed]
Schuller Y,Arends M,Körver S,Langeveld M,Hollak CEM, Adaptive pathway development for Fabry disease: a clinical approach. Drug discovery today. 2018 Jun     [PubMed]
Kubo T, Fabry disease and its cardiac involvement. Journal of general and family medicine. 2017 Oct     [PubMed]
Ferreira CR,Gahl WA, Lysosomal storage diseases. Translational science of rare diseases. 2017 May 25     [PubMed]
Baig S,Vijapurapu R,Alharbi F,Nordin S,Kozor R,Moon J,Bembi B,Geberhiwot T,Steeds RP, Diagnosis and Treatment of the Cardiovascular Consequences of Fabry Disease. QJM : monthly journal of the Association of Physicians. 2018 Jun 6     [PubMed]
Madsen CV,Christensen EI,Nielsen R,Mogensen H,Rasmussen ÅK,Feldt-Rasmussen U, Enzyme Replacement Therapy During Pregnancy in Fabry Patients : Review of Published Cases of Live Births and a New Case of a Severely Affected Female with Fabry Disease and Pre-eclampsia Complicating Pregnancy. JIMD reports. 2018 Aug 17     [PubMed]
Fukuda Y,Onishi T,Suzuki A,Tanaka H,Fukuzawa K,Yoshida A,Kawai H,Hirata KI, Follow-up of Cardiac Fabry Disease Treated by Cardiac Resynchronization Therapy. CASE (Philadelphia, Pa.). 2017 Aug     [PubMed]
Arends M,Wijburg FA,Wanner C,Vaz FM,van Kuilenburg ABP,Hughes DA,Biegstraaten M,Mehta A,Hollak CEM,Langeveld M, Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Molecular genetics and metabolism. 2017 Jun     [PubMed]
Lenders M,Hennermann JB,Kurschat C,Rolfs A,Canaan-Kühl S,Sommer C,Üçeyler N,Kampmann C,Karabul N,Giese AK,Duning T,Stypmann J,Krämer J,Weidemann F,Brand SM,Wanner C,Brand E, Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet journal of rare diseases. 2016 Jun 29     [PubMed]
Ersözlü S,Desnick RJ,Huynh-Do U,Canaan-Kühl S,Barbey F,Genitsch V,Müller T,Cheetham M,Flammer A,Schaub S,Nowak A, Long-Term Outcomes of Kidney Transplantation in Fabry Disease. Transplantation. 2018 Apr 24     [PubMed]
Siegenthaler M,Huynh-Do U,Krayenbuehl P,Pollock E,Widmer U,Debaix H,Olinger E,Frank M,Namdar M,Ruschitzka F,Nowak A, Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. International journal of cardiology. 2017 Dec 15     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Surgery-Urologic. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Surgery-Urologic, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Surgery-Urologic, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Surgery-Urologic. When it is time for the Surgery-Urologic board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Surgery-Urologic.